New hope for lung cancer patients when first targeted therapy stops working
Disease control
Recruiting now
This study tests whether a higher dose of the targeted drug furmonertinib, either alone or combined with chemotherapy, can help people with advanced EGFR-mutant non-small cell lung cancer whose first targeted treatment stopped working. About 60 participants will be randomly assig…
Phase: PHASE2 • Sponsor: Jialei Wang • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC